Funding

Laboratory research
#Clinical trials #FDA #Funding #Orphan drugs #Rare disease

FDA awards grants to seven clinical trials for orphan products

The US Food and Drug Administration (FDA) has announced seven new clinical trial grants awarded under the Orphan Products Grants Program for clinical trials to address the unmet needs of people affected by rare diseases. In total, clinical researchers will receive approximately $17.2 million over the next four years. Newly… Read More

#News #Regulatory

#Antimicrobial resistance (AMR) #Cystic fibrosis #Funding #LifeArc #Medicines Discovery Catapult (MDC)

£3m accelerates new drugs for lung infections in cystic fibrosis

The Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate has announced the first cohort of drug discovery projects to receive its Collaborative Discovery Programme (CDP) funding. The £3 ($3.9) million programme, funded by LifeArc, will support six early-stage novel antimicrobial projects over two years to accelerate new treatments for lung infections… Read More

#Business & Investment #News

#Brain cancer #Cancer Research UK #Funding #Oncology #Paediatrics

£3m boost to paediatric brain cancer research

Experts from Cancer Research UK Children’s Brain Tumour Centre of Excellence in Cambridge, UK are set to share around £3.2 ($4.2) million to find and test better and less toxic ways to treat children’s brain tumours. The funding announcement comes during Childhood Cancer Awareness Month. Read More

#Cancer Research #News

Vaccine
#Clinical trials #Drug development #Funding #Immunology / Virology & Vaccines #Respiratory #Vicebio

New financing and clinical trial for RSV/hMOV bivalent vaccine

Vicebio has announced a $100 million Series B financing, which will be used to develop next-generation vaccines for respiratory viruses.   The development will utilise Vicebio’s Molecular Clamp technology, discovered at The University of Queensland. The technology stabilises viral glycoproteins in their highly immunogenic ‘prefusion’ conformation, crucial for… Read More

#News

#Biotechnology #Cardiometabolic diseases #Diabetes #Funding #Novo Nordisk #Pioneer Group

UK biotech Golden Ticket programme open for applications

Pioneer Group has teamed up with global healthcare company Novo Nordisk to launch a ‘Golden Ticket’ programme designed to help accelerate innovations in cardiometabolic health. The Golden Ticket programme is aimed at early-stage biotech companies focused on novel drug targets and transformational medicines in cardiometabolic diseases, rare blood and rare… Read More

#Business & Investment #News

Demyelination of neuron
#Amyotrophic lateral sclerosis (ALS) #Animal models #Charity #Funding #MND #NRG Therapeutics

mPTP Inhibitors block mitochondrial dysfunction in ALS

NRG Therapeutics has been awarded a non-dilutive grant from Target ALS Foundation to support its discovery programme for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neurone disease. It is one of five recipients of the 2024 In Vivo Target Validation grants… Read More

#News

#Autoimmune disease #EVOQ Therapeutics #Funding #National Institutes of Health (NIH)

$2 million in funding for autoimmune nanodisc therapies

EVOQ Therapeutics has received a $2 million grant from the National Institutes of Health (NIH) to advance novel therapies for autoimmune diseases. Dr James Moon, Chief Scientific Officer of EVOQ Therapeutics, said: "This support will enable us to accelerate the development of our platform, which we believe could offer significant… Read More

#Business & Investment #News

Two scientists working in a research laboratory
#Cancer research #Cancer therapeutics #Funding #Innovate UK #Oncology

Cancer drug discovery projects receive £12 million

Twenty-three companies will benefit from a share of £12 ($15.8) million from the Innovate UK Cancer Therapeutics programme. The Cancer Therapeutics programme focuses on developing life-changing cancer treatments, including immunotherapies and vaccines. It also supports projects addressing unmet medical needs for treating childhood and young persons’ cancers. The investment from… Read More

#Business & Investment #Cancer Research #News

World Parkinson's Day
#Charity #Funding #Neurodegenerative disorders #Neuroscience #Parkinson's

Parkinson’s researchers receive nearly $3 million in grant funding

The US Parkinson’s Foundation has invested nearly $3 million for 33 grants to accelerate Parkinson’s disease (PD) research. The research grants will fund scientists conducting studies across various aspects of PD to bring forward new therapies, treatments, and ultimately a cure for the disease. Read More

#News

GBP pound sterling funding
#Drug discovery #Funding #Innovate UK

UK drug discovery companies receive share of £17.8M fund

Therapeutics companies developing immunotherapies, mRNA vaccines and anti-inflammatory therapies have been chosen to receive funding from Innovate UK Biomedical Catalyst. In total, thirty projects will receive a share of £17.8 ($23.5) million from Biomedical Catalyst, Innovate UK’s flagship grant funding mechanism. Biomedical Catalyst was created to help small and medium-sized… Read More

#Business & Investment #News

#Funding #Investment #Oncology #Talus Biosciences #Transcriptomics

Talus raises $11.2M to target undruggable transcription factors

Talus Bioscience has raised $11.2 million in new venture funding from a Seed+ round. The funding round was led by Two Bear Capital, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC, and BoxOne Ventures. The money will be invested to advance Talus Bio’s therapeutic programmes, which… Read More

#Business & Investment #News

#Cell therapy #Funding #Japan #Oncology #Shinobi Therapeutics

Shinobi Therapeutics secures $59M grant for iPS-T cell therapy

Shinobi Therapeutics has been awarded up to $59 million in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). The funds will support the development of Shinobi's lead iPS-T cell programme targeting GPC3+ tumours. Shinobi also announced an extension of its Series A round, bringing the… Read More

#Business & Investment #News

Human brain
#Funding #Lario Therapeutics #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Lario Therapeutics awarded $6m for Parkinson’s drug research

Biopharmaceutical company Lario Therapeutics has been awarded a $6 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to fund Lario’s preclinical programme investigating selective CaV2.3 calcium channel inhibition as a novel and disease-modifying approach for treatment of… Read More

#News

#Funding #Mission Therapeutics #Neurodegenerative disorders #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Mission awarded $5.2m for disease-modifying Parkinson’s treatment

Mission Therapeutics has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK. The funding will help advance Mission’s potential disease-modifying treatment for Parkinson’s disease (PD), MTX325. MTX325 is a potent, selective, small molecule brain-penetrant USP30 inhibitor, which is designed to protect dopamine-producing… Read More

#Business & Investment #Editor's Choice #News

#Cancer research #Clinical trials #Funding #iOnctura #Non-small cell lung cancer (NSCLC) #Seed funding

iOnctura announces €80m to progress pipeline  

iOnctura has closed an €80 million Series B financing to continue developing a portfolio of precision oral small molecules that target cancers in novel ways.   The funding round was led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council… Read More

#Business & Investment #Cancer Research #News